liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization
Dep. of medicine and cardioloy Aarhus, Danmark.
Ullevål, Norge.
Show others and affiliations
2002 (English)In: European Heart Journal, ISSN 0195-668X, Vol. 23, no 15, 1213-1218 p.Article in journal (Refereed) Published
Abstract [en]

Aims The FRISC II trial demonstrated that, for patients with unstable coronary artery disease, an early invasive strategy following acute treatment with dalteparin and aspirin, was superior to a more conservative approach. We evaluated whether it is beneficial to extend treatment with dalteparin to patients eligible for revascularization but for whom these procedures are performed after the initial hospital stay. Methods and Results As a subanalysis of FRISC II, the efficacy and clinical safety of extended dalteparin treatment (5000 or 7500 IU. 12 h-1 to day 90) compared with placebo was assessed in 1601 patients randomized to a non-invasive group who underwent revascularization only when necessary because of recurring symptoms, (re)infarction, or severe ischaemia. By day 90, 440 patients had undergone revascularization: 267 of these procedures occurred during the double-blind period. All patients initially received acute treatment (5-7 days from day 1) with dalteparin (120 IU / kg-1 12 h-1). The incidence of death and/or myocardial infarction was monitored until revascularization or day 45 and until revascularization or day 90. There was a significant difference in the estimated probability of death and/or myocardial infarction until revascularization or day 90 in favour of dalteparin (log-rank test, P=0╖0415) and there was a significant reduction in death and/or myocardial infarction in favour of extended dalteparin treatment at day 45, with a 57% relative risk reduction (P=0╖0004). At day 90 the relative risk reduction was 29%. The safety profile of extended dalteparin treatment was similar to that of acute usage. Conclusion Extended dalteparin treatment for up to 45 days is effective and safe as a bridging therapy for patients with unstable coronary artery disease awaiting revascularization. ⌐ 2002 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved.

Place, publisher, year, edition, pages
2002. Vol. 23, no 15, 1213-1218 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-27167DOI: 10.1053/euhj.2001.3077Local ID: 11816OAI: diva2:247718
Available from: 2009-10-08 Created: 2009-10-08 Last updated: 2013-09-11

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Swahn, Eva
By organisation
Faculty of Health SciencesCardiologyDepartment of Cardiology
In the same journal
European Heart Journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 17 hits
ReferencesLink to record
Permanent link

Direct link